The utilisation of rational design at the DNA level to improve the production of biotherapeutics is another of the ways in which Oxford Genetics is utilizing its proprietary SnapFast™ platform.
A limiting factor in the efficient production of biotherapeutics is the availability of vectors and cellular systems that will express the genes of interest at levels high enough to support the eventual commercial supply requirements. Many of the vectors currently in use have highly variable levels of transcription in different cellular contexts and show little or no expression in many cells or tissues. This severely restricts their general utility for recombinant protein production or virus production for gene therapy.
Oxford Genetics is overcoming these limits by the creation of proprietary vectors and cellular expression systems that enable the manufacture of proteins and virus to rigorous tolerances of purity, potency and safety.